Against this background we set out to validate an HLA-matched unrelated donor selection algorithm for patients with AML and MDS which was essentially aimed at reducing the inhibitory potential of donor NK cells and increasing the activating potential by donor selection based on information on KIR2DS1 and KIR3DL1 (12, 13). Here, KIR3DL1 is linked to acute myeloid leukemia.